Tagrisso approved in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
21 December 2020 07:05 GMT Tagrisso approved in the US for the adjuvant treatmentof patients with early-stage EGFR-mutated lung cancer Approval based on unprecedented results from the ADAURA Phase III trialwhere Tagrisso reduced the risk of disease recurrence or death by 80% AstraZeneca's Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. Tagrisso is indicated for EGFRm patients whose